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Summary In order to identify the possible role of the DCC gene in neoplasms of the human female
reproductive tract, messenger RNA expression of the DCC gene was examined by reverse transcriptase-
polymerase chain reaction, and expression of the DCC gene product was detected immunohistochemically.
While histologically normal endometrium. cervical epithelium and ovary expressed detectable mRNA of the
DCC gene, three of eight (37%) endometrial carcinomas, one of two (50%) cervical carcinomas and 9 of 22
(41%) ovarian malignant tumours had significantly reduced or negligible DCC expression, and another
endometrial carcinoma and two other ovarian tumors underexpressed DCC when compared with histologically
normal endometrial or ovarian tissues. Impaired DCC mRNA expression was detected more frequently in
grade 3 ovarian epithelial tumours than in grade 1 tumours (P= 0.002). Loss of expression of the DCC gene
product detected by immunohistochemistry significantly correlated with the loss of mRNA expression in
ovarian carcinomas (P = 0.01 by chi-square test) or in both endometrial and ovarian carcinomas combined
(P= 0.001). Loss of heterozygosity of the DCC gene was also evaluated by restriction fragment polymorphism
analysis of the polymerase chain reaction-amplified DNA fragment. Loss of heterozygosity of the DCC gene
was detected in one of seven (14%) informative cases of endometrial carcinomas. I of 11 (9%) informative
cases of cervical carcinomas and two of six (33%) informative cases of ovarian tumours. These results
demonstrate that inactivation of the DCC gene, especially by the loss of expression. plays a significant role in
the aetiology of neoplasms of the human reproductive tract.
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Multiple genetic changes occur in human carcinogenesis, in-
cluding the activation of proto-oncogenes and inactivation of
tumour-suppressor genes (Fearon and Vogelstein, 1990).
Oncogenes were originally identified in oncogenic retroviruses
and in tumour DNA that could transform NIH3T3 cells, and
therefore have positive roles in tumorigenesis. On the other
hand, tumour-suppressor genes are associated with transfor-
mation through the loss of normal gene function and
therefore have negative roles in tumorigenesis. Several
tumour-suppressor genes have been identified including RB
(retinoblastoma), p53, WTI (Wilms' tumour), NFI
(neurofibromatosis type 1), DCC (deleted in colon car-
cinoma), APC (adenomatous polyposis coli), MCC (mutated
in colorectal cancer) and VHL (von Hippel-Lindau) (Knud-
son, 1993). The mechanisms of inactivation of these tumour-
suppressor genes include allelic loss, chromosomal rearrange-
ments, loss of messenger RNA expression, loss of decreased
expression of the gene product, point mutation or interaction
with the viral or cellular inactivating proteins.
The DCC gene was identified at chromosome 18q21, where
allelic deletions frequently occur in colorectal cancers.
Genetic alterations of the DCC gene, including a homozy-
gous deletion of the 5' end of the gene, a point mutation
within one of the introns and a DNA insertion at the introns,
have also been identified (Fearon et al., 1990). It was shown
recently that the DCC gene spans nearly 1.4 megabases,
which makes it the largest tumour-suppressor gene identified
so far, and consists of 29 exons (Cho et al., 1994). The
sequence of DCC cDNA predicts a 1447 amino acid trans-
membrane protein with four immunoglobulin-like and six
fibronectin type III-like extracellular domains (Hedrick et al.,
1994). The 325 amino acid cytoplasmic domain has little
homology with previously characterised proteins (Hedrick et
al., 1994). While cell adhesion molecules such as E-cadherin
regulate the gap junctional intercellular communication, no
correlation between the level of the gap junctional intercel-
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lular communication and DCC expression has been found
(Mesnil et al., 1993). The role of this gene as a tumour
suppressor was demonstrated by the observation that Rat-l
fibroblasts in which DCC expression is down-regulated by
antisense RNA show a faster growth rate, anchorage inde-
pendence and tumorigenicity in nude mice (Narayanan et al.,
1992). The introduction of chromosome 18, on which the
DCC gene is located, into a human colon carcinoma cell line,
COKFu, which does not express DCC gene, results in sup-
pression of tumorigenicity of these cells in athymic nude mice
and inhibition of growth in soft agar (Tanaka et al., 1991),
which are consistent with the activity of a tumour-suppressor
gene. The tumorigenicity of another colon carcinoma cell
line, SW480.7, is also suppressed by the incorporation of
chromosome 18 (Goyette et al., 1992).
Allelic loss of the DCC gene has frequently been observed
not only in colorectal carcinomas but also in gastric (Uchino
et al., 1992), oesophageal (Huang et al., 1992), breast
(Devilee et al., 1991) and prostatic carcinomas (Gao et al.,
1993). Expression of the DCC gene has been detected in
many normal tissues, including brain and colonic mucosa
(Fearon et al., 1990), while its expression is absent or greatly
reduced in colorectal (Itoh et al., 1993), pancreatic (H6hne et
al., 1992) and prostatic carcinomas (Gao et al., 1993) and
malignant gliomas (Scheck and Coons, 1993). However, little
is known about the possible role of the DCC gene in neo-
plasms of the human female reproductive tract. Accordingly,
we have analysed the expression of DCC mRNA and protein
and loss ofheterozygosity of the DCC gene in these tumours.
We report here that the inactivation of DCC occurs rather
frequently in these neoplasms.
Materials and methods
Tissue preparations ofDNA and RNA
Samples used in this study were from patients who had been
admitted to the Department of Obstetrics and Gynecology at
the Osaka University Hospital in Osaka, Japan. No initialchemotherapy or radiation therapy was performed prior to
tumour excision. Surgically removed tissues were sampled for
histopathological diagnosis and the remainder were quickly
frozen for extraction of RNA or DNA or for immunohisto-
chemical analysis. Histological classification of tumours was
in accordance with the WHO international system. Surgical
staging was established according to the Intenational Feder-
ation of Gynecology and Obstetrics. A total of 32 neoplasms,
including eight endometrial adenocarcinomas, 22 ovarian
malignant and low-grade malignant tumours (three endome-
trioid carcinomas, five mucinous adenocarcinomas, one
mucinous carcinoma of low malignant potential ten serous
adenocarcinomas, one clear cell carcnoma, one immature
teratoma and one dysgerminoma) and two cevical carcin-
omas were evaluated for the mRNA expression of the DCC
gene. RNA was extracted with guanidinium isothiocyanate
followed by centrifgation in a caesium chloride solution.
RNA was also extracted from histologically normal ovary,
endometrium, cervix and colon mucosa. Expression of the
DCC gene product was detected immunohistochemically in a
total of 18 neoplasms, including in five endometrial adeno-
carcinomas and 13 malignant ovarian tumours (eight serous
adenocarcinomas, two mucinous adenocarcinomas and three
endometrioid adenocarcinomas). Loss of heterozygosity of
the DCC gene was also anablsed in a total of 95 neoplasms
including 29 cenrical squamous cell carcnomas, 34 ovarian
tumours, and 32 endometrial adenocarcnomas and seven
endometrial atypical hyperplasias. High moleular weight
DNA was extracted following the procedures previously des-
cribed (Enomoto et al., 1990). DNA was also extracted from
white blood cells or histologically normal myometrium from
the patients.
Reverse transcription-polymerase chain reaction analysis
For complementary DNA synthesis, 1 lg of total cellular
RNA was annealed with random hexamers (pd(N)6) at 26'C
for 10 min and transcribed with 10 units of AMV reverse
transcriptase (Gibco-BRL) in the presence of the ribo-
nuclease inhibitor RNasin (1 ILl; Promega, Madison, WI,
USA) (Enomoto et al., 1993a). A cDNA aliquot, correspond-
ing to 200-500 ng of RNA, was used as the template of PCR
amplification. Primers used were 5'-AGCCTCATITrTCAG-
CCACACA-3' for antisense primer, which corresponds to
nucleotides 1218-1198 in the cDNA sequences, and 5'-TT-
CCGCCATGGT-TI-IIAAATCA-3' for sense primer, which
corresponds to nucleotides 986-1007 (Fearon et al., 1990).
For an internal control of RT-PCR, a 319bp fragment of
P-actin was simultaneously amplified using primers 5'-ATCA-
TGmTTGAGACCI-TCAA-3' and 5'-CATCTCTTGCTCGA-
AGTCCA-3' (Fuqua et al., 1990). The PCR mixture (total
50 il) contained cDNA (200-500 ng), 0.5 pm of each primer
for DCC, 0.05 gIM of each primer for P-actin, 100gIM of each
deoxynucleotide triphosphate, 0.5 U of Taq polymerase
(Perkin-Elmer Cetus, Norwalk, CT, USA), 1.5 mM magne-
sium chloride, 50 mM potassium chloride, 1OmM Tris-HCI
(pH 8.3) and 0.01 % gelatin. One cycle consisted of 1 min at
94-C (denaturation), 1 min at 55C (annaling) and 1 min at
72-C (elongation) and a total of 28 cycles of PCR amplifica-
tion was performed. The PCR products were fractionated in
12% polyacrylamide gels, and DNA fragments were visual-
ised by staining with ethidium bromide. Quantitation was
done by densitometric analysis using the software NIH
Image version 1.44.
Immunohistochemistry
The tissue localisation of DCC protein was determined
immunohistochemically by the avidin-biotin-peroxidase
complex method on frozen sections. Sections (4pm) were cut
with a cryostat, placed on glass slides coated with 0.02%
poly-L-lysine (Sigma, St Louis, MO, USA), and fixed with
acetone for 10min at room temperature. The sections were
immersed in 0.3% hydrogen peroxidase to block endogenous
peroxidase activity, and the staining procedures were then
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carried out according to the manufacturer's recommendation
(Vector Laboratories, Buringhame, CA, USA). A mono-
clonal antibody to the DCC gene product (Ab-1) (Oncogene
Science, Uniondale, NY, USA) was used as primary antibody
for the present immunohistochemistry. Sections from normal
proliferative endometrium and normal ovary were used as
positive controls for the expression of DCC. Sections on
which normal mouse serum were incubated instead of the
corresponding primary antibody were used as negative con-
trols. The relative number of immunoreactive cells was
graded from negative to grade 3 (+ + +) as follows. (-, -no
staining was observed in any tumour cell; +, less than 10%
of the tumour cells were stained positively, + +, between
10% and 50% of the tumour cells were stained positively,
+ + +, more than 50% of the tumour cells were stained
positively.)
Detection ofloss ofheterozygosity by PCR-RFLP analysis
PCR amplification was performed to generate 367 bp DNA
fragments around the polymorphic MspI sites of the DCC
gene. The PCR mixture was prepared from a GeneAmp
DNA amplification reagent kit (Perklin-Elmer Cetus) follow-
ing the manufacturer's instructions. Primers used were 5'-
TTGCACCATGCTGAAGATTCTT-3' (upstream) and 3'-
ATTTCAGTAGTCCCCCTCCCA-5'(downstream) (Parry et
al., 1991). DNA (SOOng) was added to the 50id reaction
mixture and incubated initially for 5 min at 100-C. Then 0.25
units of Taq polymerase was added. One cycle consisted of
I min at 95-C (denaturation), I min at 59 C (annealing) and
1 min at 72 C (elongation) and a total of 35 cycles of PCR
amplification were performed. A 10Il aliquot of this PCR
product was digested with 100 U of the restriction endo-
nuclease MspI (Toyobo, Japan) at 3rC for 6 h and electro-
phoresed in a 12% non-denaturing polyacrylamide gel. DNA
fragments were visualised by staining with ethidium bromide.
The amplified 367 bp fragment was cut into 227 bp and
140 bp fragments when the restriction site was present. Cases
in which DNA derived from white blood cells (WBCs) yield-
ed three fragments (367 bp, 227 bp and 140 bp) were con-
sidered informative, and DNA derived from the tumours was
further analysed for loss of heterozygosity.
ReIts
Loss ofexpression ofthe DCC gene
Expression of mRNA from the DCC gene was examined in a
total of 32 neoplasms of the human female reproductive tract
by RT-PCR analysis, as well as in histologically normal
ovary, uterine endometrium, cervix and colonic mucosa as
positive controls. PCR amplification was performed from the
complementary DNA to generate the 233 bp fragment of the
DCC gene and the 319 bp fragment ofA-actin simultaneous-
ly. Both fragments were successfully amplified in the his-
tologically normal tissues, suggesting that the DCC gene is
expressed in the normal tissues of the ovary, uterine endo-
metrium, cervix, and colon mucosa (Figure 1). On the other
hand, the 233 bp fragment of the DCC gene was amplified
little or not at all, while the 319 bp fragment of the P-actin
gene was successfilly generated in three of eight (37%)
endometrial adenocarcinomas, one of two (50%) cervical
squamous cell carcinomas and 9 of 22 (41%) ovarian
tumours [one of three endometrioid carcinomas (33%), one
of six mucinous carcinomas (17%), five of ten serous car-
cinomas (50%), one clear cell carcinoma and one of two
germ-line tumours], suggesting that DCC mRNA expression
was significantly reduced or absent in these tumours (Table
I). Moreover, in one endometrial carcinoma (case 6) and two
serous adenocarcinomas of the ovary (cases 3 and 7), the
intensity of the 233 bp fragment of the DCC gene was only
about one-third of the intensity of those derived from the
histologically normal endometrial or ovarian tissues. In order
to test the validity of the experiment regarding the semiquan-Apo
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Figre I Demonstration of loss of expression in the DCC gene by RT-PCR analysis. PCR amplification was performed on
complementary DNA to generate a 233 bp fragment of the DCC gene and a 319 bp fragment of the P-actin gene simultaneously.
The PCR products were fractionated in a 12% polyacrylamide gel and visualised by staining with ethidium bromide. Note that the
319 bp fragment of P-actin was successfully generated in all the samples analysed, whereas fragments of the DCC were not
amplified in lanes 3. 7. 10. 13. 14 and 15, suggesting the loss of expression in these tumours. In lane 4. intensity of the 233 bp
fragment of DCC was weak. suggesting decreased DCC expression. Lanes 1-5, endometrial carcinomas, lanes 6 and 7. cervical
carcinomas: lanes 8-15. ovarian carcinomas; lanes 16- 18. normal uterine endometrium. normal ovary, and normal colon
mucosa.
Table I Expression of the DCC gene in the neoplasms of the
human reproductive tract
DCC expression
Immunohisto-
Case Histology Age Grade Stage mRNAa chemistr-t
Endometrial carcinoma
I Endometrioid 50 1 1 + NT
2 Endometnroid 67 1 1 + NT
3 Endometrioid 44 2 3 + + +
4 Endometrioid 28 2 1 - -
5 Endometrioid 72 3 3 +
6 Endometrioid 49 3 3 + NT
7 Endometrioid 68 3 2
8 Endometrioid 66 3 3
Ovarian tumour
I Serous 39 1 1 + +
2 Serous 50 1 3
3 Serous 62 2 3 + +
4 Serous 52 2 4 + + +
5 Serous 55 2 3 + + +
6 Serous 31 2 3 - -
7 Serous 61 3 4 + +
8 Serous 53 3 3 - NT
9 Serous 58 3 3
10 Serous 46 3 3 - NT
11 Mucinous 29 1 1 + NT
12 Mucinous 54 1 2 +
13 Mucinous 55 1 2 + NT
14 Mucinous 38 1 3 + + + +
15 Mucinous 47 3 1 - NT
16 Mucinous (LPM)b 63 NA I + NT
17 Endometrioid 55 2 2 + +++
18 Endometrioid 47 2 3 + + +
19 Endometrioid 39 3 3
20 Clear cell 49 3 1 - NT
21 Dysgerminoma 19 NA I - NT
22 Immature teratoma 21 2 1 + NT
Cervical carcinoma
I Squamous cell 56 3 1 - NT
2 Squamous cell 62 1 1 + NT
a+, Intensity equal to that observed in normal tissue; ±.
approximately one-half of normal; -. no detectable expression or
much less than half of normal. b+ + +, more than 50% of the
tumour cells were stained positively; + +. between 10% and 50% of
the tumour cells were stained positively; +, less than 10% of the
tumour cells were stained positively; -, no staining was observed in
any tumour cell. Abbreviations: NT. not tested; LPM. low potential
malignancy; NA. not applicable.
titative assay, the following control experiments were per-
formed. Complementary DNA derived from normal endome-
trium which expressed DCC was diluted 2-fold serially with
the cDNA derived from the endometrial carcinoma (case 4),
which did not express DCC, and 20, 28, and 35 cycles of
PCR amplification were performed. The PCR products were
a
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Figue 2 Demonstration of the validity of RT-PCR as a semi-
quantitative assay. Complementary DNA denrved from normal
endometrium, which expressed DCC, was diluted 2-fold serially
with the cDNA derived from endometrial carcinoma (case 4)
which did not express DCC, and 28 cycles of PCR amplification
were performed. The PCR products were fractionated in 12%
polyacrylamide gels, and DNA fragments were visualised by
staining with ethidium bromide (a). Quantitation was done by
densitometric analysis (b). Lane 1, undiluted normal endo-
metrium; lane 2. 1 2 dilution, lane 3. 1 4; lane 4. 1 8; lane 5. 1 16;
lane 6, undiluted endometnral carcinoma (case 4).
fractionated in 12% polyacrylamide gels, and DNA frag-
ments were visualised by staining with ethidium bromide.
Quantitation was done by densitometric analysis. The
amount of PCR product of the DCC gene correlated well
with the proportion of the cDNA derived from normal
endometrium after 28 cycles of PCR amplification (Figure 2)
but did not correlate well after 35 cycles, probably because
the reaction plateaued. PCR for 20 cycles did not yield
sufficient product to be detected (data not shown). Densi-
tometric analysis showed that the ratio of DCC/I-actin was
1.10, 0.79, 0.63, 0.33, 0.16 for 1-. 2-, 4-, 8- and 16-fold
dilution respectively. From these observations we conclude
that DCC expression was reduced in cases 6 (endometrial
carcinoma) 3 and 7 (ovarian carcinoma), in DCC' -actin
ratios were 0.29, 0.38 and 0.16 respectively.
Association of impaired DCC mRNA expression with his-
tological grade or clinical stage was evaluated. Impaired
expression was observed in one of three (33%), one of one
(100%) and two of five (50%) endometrial carcinomas of
stage 1, 2 and 3, respectively, and two of four (50%), none of
three (0%), seven of ten (70%) and both (100%) ovarian
epithelial tumours of stage 1, 2, 3 and 4 respectively. Thus,
there was no clear association of impaired expression with
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clinical stage. Conversely, impaired expression was observed
in none of two (0%), one of two (50%) and three of four
(75%) endometrial carcinomas of grade 1, 2 and 3, respec-
tively, and one of seven (14%), two of six (33%) and all
seven (100%) ovarian epithelial tumours of grade 1, 2 and 3
respectively (Table H). The prevalence of impaired DCC
expression in grade 3 ovarian epithelial tumours was signi-
ficantly higher than that in grade 1 tumours (P =0.002 by
Fisher's exact test). Therefore reduced or absent expression
of the DCC gene tended to occur in tumours of higher
histological grade. In the ovary, decreased or loss of expres-
sion was found more frequently in serous tumours (7/10,
70%) than in mucinous tumours (1/6, 17%).
Immuzohistochemical detection ofthe DCC geneproduct
The DCC gene product was examined immunohistochemi-
cally in five endometrial adenocarcinomas and 13 ovarian
Table k Summary of impaired mRNA expression of the DCC gene
in endometrial and ovarian adenocarcinoma
Grade Imnpired DCC expreson
Eadometrial adenocarcinoma
GI 0/2 0%
G2 1/2 50%
G3 3/4 25%
Ovarian adenocarcinoma
GI 1/7 14%
G2 2/6 33%
G3 7/7k 100%
aSignificantly higher than GI ovarian carciomas (P = 0.002 by
Fisher's exact test).
a
b
adenocarcinomas. While the normal endometrium and the
surface epithelium of the normal ovary showed strong
positive staining, many tumours showed either no staining or
weak staining to a variable extent (Figure 3). Even in a single
tumour, staining intensity varied from area to area, although
there was a tendency that it was less evident in areas of
histologically more aggressive lesion. Four of five endo-
metrial carcinomas and 5 of 13 ovarian adenocarcinomas
showed negative staining (Table I). Three endometrial adeno-
carcinomas (cases 4, 7 and 8) and four ovarian adeno-
carcinomas (cases 2, 6, 9 and 19) which showed negative
staining did not express DCC mRNA. Two ovarian adeno-
carcinomas which showed weak positive staining (cases 3 and
7) revealed reduced DCC mRNA expression. The intensity of
the immunohistochemical staining correlated significantly
with the level of mRNA expression in ovarian tumours
(P= 0.01 by chi-square test) or in both endometrial car-
cinomas and ovarian tumours combined (P = 0.001 by chi-
square test). Although a single case ofendometrial carcinoma
(case 5) and a single case of ovarian adenocarcinoma (case
12) showed no stg in spite of positive DCC mRNA
expression, there was, thus, a sigicant correlation between
the mRNA expression and immunohistochemistry.
Detection ofloss ofheterozygosity in the DCC gene
Loss of heterozygosity in the DCC gene was detected by
PCR-(RFLP) analysis (Figure 4). Of a total of 102 samples
analysed, DNA derived from WBCs or the histologically
normal tissue from 7 of 32 (22%) endometrial adenocar-
cinomas, one of seven (14%) endometrial atypical hyper-
plasias, 11 of 29 (38%) cervical carcinomas and 6 of 34
(18%) ovarian tumours showed heterozygosity and were
therefore informative for the LOH analysis. DNA derived
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Fugwe 3 Immunohistochemical analysi of the DCC gene product in normal and malignant tissues of the female genital trat (a)
Glandular cells ofprolferative endometrium showed a granular staining at the cell boundaries, with weak stainmg m cytoplasm.
(b) The foci ofwell-differentiated adenocarcinoma of the uterine endomerium showed intense staining, whereas histologially more
aggressive lesion showed faint staining (arrows). (c) Poorly differentiated of the uterine endometrim showed no
staining. (d) Surface epithelium of the normal ovary showed positive staining while stomal cells showed negative stainin
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Figure 4 Demonstration of loss of heterozygosity in the DCC
gene by PCR-RFLP analysis. PCR amplification was performed
to generate 367 bp fragments around the polymorphic MspI site
of the DCC gene using DNA derived from WBCs (lane N) or
tumour (lane T), and products digested with MspI were frac-
tionated in a 12% polyacrylamide gel. Digestion with MspI
yielded two bands (227 bp and 140 bp) when the restriction site
was present. DNA derived from WBCs (lane N) showed heter-
ozygosity (i.e. contained both undigested and digested fragments),
and was therefore informative. In lanes 2 and 3, the signal for the
180 bp band was significantly reduced in DNA derived from the
tumours (T) (loss of heterozygosity); however, in lanes l. three
bands were still retained in DNA denrved from the tumour (T).
Lanes -3. cases of ovarian tumour nos. 4. 7 and 22 respec-
tively.
from the tumours of those informative cases was further
analysed. Of those one of seven (14%) endometrial car-
cinomas. 1 of 11 (9%) cervical squamous cell carcinomas and
two of six (33%) ovarian adenocarcinomas showed loss of
heterozygosity at the DCC locus (Table III). In these four
cases of LOH, either the 367 bp fragment or the 227 bp and
140 bp fragments were lost in DNA derived from the
tumours.
Dis~
In this study. we analysed the possible involvement of the
DCC gene in neoplasms of the human female reproductive
tract. We show, for the first time, that the DCC gene is
frequently decreased in expression or undetectable in these
neoplasms. Significantly reduced or absent mRNA expression
was observed in about 40% of the ovarian malignant
tumours and endometrial carcinomas. Three other tumours
(one endometrial carcinoma and two serous adenocarcinomas
of the ovary) expressed DCC mRNA levels that were much
less than one-half of that of the normal tissues. Therefore,
impaired expression of the DCC gene was observed in four of
eight (50%) endometrial carcinomas and 12 of 22 (55%)
ovarian tumours. Impaired expression of mRNA was more
frequently detected in the tumours of higher histological
grade, corresponding well to the immunohistochemical
analysis. The high incidence of impaired expression of the
DCC gene is somewhat similar to the frequencies reported
for other human malignancies such as colorectal (57%), pan-
creatic (50%) and prostatic carcinomas (86%) (H6hne et al.,
1992; Itoh et al., 1993; Gao et al., 1993). We also showed
that loss of heterozygosity of the DCC gene was detected in
14% of endometnral carcinoma, 9% of cervical carcinomas
and 33% of ovarian tumours, which is not as frequent as
reported for colorectal or gastric carcinoma. Loss of heter-
ozygosity of the DCC gene in endometrial carcinoma was
previously examined by Okamoto et al. (1991a) and Imamura
et al. (1992) using the probe OLIVIEIO, and loss of heter-
ozygosity was found in one ofeight (13%) and 4 of 13 (31%)
endometrial carcinomas respectively, similar to the present
data. Chenevix-Trench et al. (1992) reported loss of heter-
ozygosity in about 40% of adenocarcinomas of the ovary,
Table III Tumours with loss of heterozygosity in the DCC gene
DCC expression
Immunohisto-
Case Histology Age Grade Stage mRVA chemistrn
Endometrial carcinoma
9 Endometrioid 56 3 2 NT NT
Ovarian tumour
7 Serous 61 3 4 + +
22 Immature teratoma 21 1 + NT
Cervical carcinoma
3 Squamous cell 73 2 2 NT NT
NT. not tested. For key to symbols. see footnotes to Table I.
which is also similar to the present data. However, intensive
analysis using several chromosomal markers which localise to
18q showed that the smallest region of overlap appears to
exclude the DCC gene (18q21.3) and to be between D18S5
(18q21.3-qter) and D18SI1 (18q23) loci, suggesting that
another locus, in addition to or apart from DCC, may be
involved in ovarian carcinogenesis. Nevertheless, the DCC
gene is implicated in tumorigenesis of endometrium and
ovarian epithelium since impaired expression has frequently
been observed in such tumours. In colorectal carcinoma,
DCC expression was reduced during tumour progression
from intramucosal to invasive carcinoma (Kikuchi-Yanoshita
et al.. 1992), suggesting that the DCC gene may act as a
metastatic suppressor. Similarly. impaired DCC expression
was detected in 100% of colorectal tumours with liver metas-
tasis (Itoh et al., 1993). Loss of heterozygosity of the DCC
gene was observed more frequently in metastatic liver
tumours from colon than in primary colorectal carcinomas
(Ookawa et al., 1993). In endometrial carcinomas and
ovarian epithelial tumours. we found that impaired DCC
expression occurs more frequently in tumours of higher his-
tological grade, suggesting that alteration in the DCC gene is
associated with the aggressiveness of these tumours.
Among the tumour-suppressor genes, alterations of the
p53 gene are observed in a wide variety of human cancers
and are currently the most commonly found alterations
associated with human cancer (Nigro et al., 1989; Levine et
al.. 1991). Mutations of both p53 alleles, one through dele-
tion and the other through a base substitution, occur in
many human cancers including endometrial carcinoma (Oka-
moto et al., 1991a; Enomoto et al., 1993b) and ovarian
carcinoma (Mazars et al., 1991; Okamoto et al., 1991b). The
mechanism of inactivation of the RB tumour-suppressor gene
seems to be different from that of the p53 gene. There is no
correlation between the loss of expression of the RB protein
and loss of heterozygosity of the RB gene in bladder car-
cinoma (Ishikawa et al., 1991) and breast cancer (Borg et al..
1992). We previously reported that loss of heterozygosity
does not accompany loss of mRNA expression in an endo-
metrial carcinoma (Enomoto et al., 1993a). Inactivation of
the RB gene seems to occur as a result of mutations in both
alleles rather than a loss of one allele and mutation in
another allele, as observed for p53. The association of loss of
expression with the loss of heterozygosity in the present
study was therefore evaluated. Of seven cases of endometrial
carcinomas which were informative for loss of heterozygosity
analysis, a single case (case 7) was also analysed for DCC
expression. Loss of mRNA expression was observed in this
case, although there was no concomitant loss of heterozy-
gosity. Of nine cases of ovarian carcinomas which were
informative for loss of heterozygosity analysis, four cases
(cases 4. 5, 7 and 22) were also analysed for DCC expression.
Loss of heterozygosity was detected in two cases (cases 7 and
22). Decreased mRNA expression accompamed LOH in one
case (case 7). but DCC expression was not altered in another
case of immature teratoma (case 22). In the latter tumour.
another locus which is located very close to the DCC gene
may function in carcinogenesis as proposed by Chenevix-
Trench et al. (1992). Among ovarian tumours in which loss
466TaW in gyncological tumours
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of heterozygosity was not observed (cases 4 and 5), decreased
mRNA expression was observed in only a single case (case
4). These findings suggest that inactivation of the DCC
tumour-suppressor gene does not necessarily occur through
deletion in one allele and mutation in the other allele, as
observed for the p53 gene. Since the exons of the DCC gene
are scattered over approximately 370 kb, and the locus we
analysed in the present study, D18S8, is in the middle of this
segment, rearrangements or partial deletions of DCC may
occur upstream or downstream of this locus. The present
findings suggest that inactivation of the DCC gene can occur
through mutations in both alleles, which could lead to loss of
expression of the gene. The observation that the prevalence
of loss of expression is higher than loss of heterozygosity
seems to support this hypothesis.
In conclusion, inactivation of the DCC gene by loss of
expression or by allelic loss occurs rather frequently in neo-
plasms of the human female reproductive tract, and therefore
may play an important role as one of the alterations in
multistep carcinogenesis. Other types of DCC alterations,
such as insertions, deletions or point mutations, warrant
further study.
AckdowIdgeUeets
The authors wish to express their appreciation to Dr Alan 0 Prean-
toni, National Cancer Institute Frederick, MD, USA, for helpful
comments.
Referenes
BORG A. ZHANG Q-X. ALM P. OLSSON H AND SELLBERG G_ (1992).
The retinoblastoma gene (RB) in breast cancer: allele loss is not
correlated with loss of gene protein expression. Cancer Res., 52,
2991-2994.
CHENEVIX-TRENCH G. LEARY J. KERR J, MICHEL J. KEFFORD R.
HURST T. PARSONS PG. FREIEDLANDER M AND KHOO SK.
(1992). Frequent loss of heterozygosity on chromosome 18 in
ovanan adenocarcinoma which does not always include the DCC
locus. Oncogene, 7, 1059-1065.
CHO KR. OLINER JD. SIMONS JW. HEDRICK L, FEARON ER. PREIS-
INGER AC. HEDGE P. SILVERMAN GA AND VOGELSTEIN B.
(1994). The DCC gene: structural analysis and mutations in
colorectal carcinomas. Genomics, 19, 525-531.
DEVILEE P. vAN VLIET M. KUIPERS-DUKSHOORN N. PEARSON PL
AND CORNELISSE CJ. (1991). Somatic genetic changes on
chromosome 18 in breast carcinomas: is the DCC gene involved?
Oncogene. 6, 311-315.
ENOMOTO T. INOUE M. PERANTONI AO. TERAKAWA N. TANI-
ZAWA 0 AND RICE JM. (1990). K-ras activation in neoplasms of
the human female reproductive tract. Cancer Res.. 50, 6139-
6145.
ENOMOTO T. FUJITA M. INOUE M. NAKAZAWA-MIYAMOTO A.
TANIZAWA 0 AND NOMURA T. (1993a). Alterations of the Rb
gene and its association with Ki-ras activation and p53 inactiva-
tion in endometrial adenocarcinoma. Mol. Carcinogen., 8, 132-
137.
ENOMOTO T. FUJITA M. INOUE M. RICE JM. NAKAJIMA R. TANI-
ZAWA 0 AND NOMURA T. (1993b). Alterations of the p53 tumor
suppressor gene and its association with activation of the c-K-
ras-2 protooncogene in premalignant and malignant lesions of the
human utenrne endometrium. Cancer Res., 53, 1883-1888.
FEARON ER AND VOGELSTEIN B. (1990). A genetic model for
colorectal tumorigenesis. Cell, 61, 759-767.
FEARON ER. CHO KR. NIGRO JM. KERN SE. SIMONS JW. RUPPERT
JM. HAMILTON SR. PREISINGER AC. THOMAS G. KINZLER KW
AND VOGELSTEIN B. (1990). Identification of a chromosome I8q
gene that is altered in colorectal cancers. Science, 247, 49-56.
FUQUA SAW. FALETTE NF AND MCGUIRE WL. (1990). Sensitive
detection of estrogen receptor RNA by polymerase chain reaction
assay. J. Vatl Cancer Inst., 82, 858-861.
GAO X. HONN KV. GRIGNON D. SAKR W AND CHEN YQ. (1993).
Frequent loss of expression and loss of heterozygosity of the
putative tumor suppressor gene DCC in prostatic carcinomas.
Cancer Res., 53, 2723-2727.
GOYETTE MC. CHO K. FASCHING CL LEVY DB, KINZLER KW.
PARASKEVA C. VOGELSTEIN B AND STANBRIDGE EJ. (1992).
Progression of colorectal cancer is associated with multiple tumor
suppressor gene defects but inhibition of tumorigenicity is
accomplished by correction of any single defect via chromosome
transfer. Mol. Cell. Biol., 12, 1387-1395.
HOHNE MW. HALATSCH M-E. KAHL GF AND WEINEL RJ. (1992).
Frequent loss of expression of the potential tumor suppressor
gene DCC in ductal pancreatic adenocarcinoma. Cancer Res., 52,
2616-2619.
HEDRICK L. CHO KR. FEARON ER. WU T-C. KINZLER KW AND
VOGELSTEIN B. (1994). The DCC gene product in cellular differ-
entiation and colorectal tumorigenesis. Genes Dev., 8, 1174-
1183.
HUANG Y. BOYNTON RF. BLOUNT PL. SILVERSTEIN RJ. YIN J.
TONG Y. McDANIEL TK. NEWKIRK C. RESAU IH, SRIDHARA R.
REID BI AND MELTZER SJ. (1992). Loss of heterozygosity
involves multiple tumor suppressor genes in human esophageal
cancers. Cancer Res., 52, 6525-6530.
IMAMURA T. ARIMA T. KATO H. MIYAMOTO S. SASAZUKI T AND
WAKE N. (1992). Chromosomal deletions and K-ras gene muta-
tions in human endometrial carcinomas. Int. J. Cancer, 51,
47-52.
ISHIKAWA J. XU HJ. HU S-X. YANDELL DW. MAEDA S. KAMI-
DONO S, BENEDICT WF AND TAKAHASHI R. (1991). Inactiva-
tion of the retinoblastoma gene in human bladder and renal cell
carcinomas. Cancer Res., 51, 5736-5743.
ITOH F. HINODA Y, OHE M, BAN T. ENDO T. IMAI K AND YACHI
A. (1993). Decreased expression of DCC mRNA in human colo-
rectal cancers. Int. J. Cancer, 53, 260-263.
KIKUCHI-YANOSHITA R, KONISHI M, FUKUNARI H, TANAKA K
AND MIYAKI M. (1992). Loss of expression of the DCC gene
during progression of colorectal carcinomas in familial adenoma-
tous polyposis and non-familial adenomatous polyposis patients.
Cancer Res., 52, 3801-3803.
KNUDSON AG. (1993). Antioncogenes and human cancer. Proc. Natl
Acad. Sci. USA, 90, 10914-10921.
LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour
suppressor gene. Nature, 351, 453-456.
MAZARS R, PUJOL P. MAUDELONDE T, JEANTEUR P AND
THEILLET C. (1991). p53 mutations in ovarian cancer: a late
event? Oncogene, 6, 1685-1690.
MESNIL M. PICCOLI C. KLEIN J-L. MORAND I AND YAMASAKI H.
(1993). Lack of correlation between the gap junctional com-
munication capacity of human colon cancer cell lines and expres-
sion of the DCC gene, a homologue of a cell adhesion molecule
(N-CAM). Jpn J. Cancer Res., 84, 742-747.
NARAYANAN R. LAWLOR KG. SCHAAPVELD RQJ. CHO KR.
VOGELSTEIN B. TRAN PB-V. OSBORNE MP AND TELANG NT.
(1992). Antisense RNA to the putative tumor-suppressor gene
DCC transforms Rat-I fibroblasts. Oncogene, 7, 553-561.
NIGRO JM, BAKER SJ. PREISINGER AC, JESSUP IM, HOSTETTER R,
CLEARY K. BINGER SH, DAVIDSON N, BAYLIN S, DEVILEE P.
GLOVCER T, COLLINS FS, WESTON A. MODALI R, HARRIS CC
AND VOGELSTEIN B. (1989). Mutations in the p53 gene occur in
diverse human tumour types. Nature, 342, 705-708.
OKAMOTO A, SAMESHIMA Y. YAMADA Y, TESHIMA S. TERA-
SHIMA Y. TERADA M AND YOKOTA J. (1991a). Alelic loss on
chromosome 17p and p53 mutations in human endometnral car-
cinoma of the uterus. Cancer Res., 51, 5632-5636.
OKAMOTO A, SAMESHIMA Y, YOKOYAMA S, TERASHIMA Y, SUGI-
MURA T, TERADA M AND YOKOTA J. (1991b). Frequent allelic
losses and mutations of the p53 gene in human ovarian cancer.
Cancer Res., 51, 5171-5176.
OOKAWA K. SAKAMOTO M. HIROHASHI S, YOSHIDA Y, SUGI-
MURA T AND YOKOTA J. (1993). Concordant p53 and DCC
alterations and allelic losses on chromosomes 13q and 14q
associated with liver metastases of colorectal carcinoma. Int. J.
Cancer, 53, 382-387.
PARRY PJ, MARKIE D. FEARON ER, NIGRO JM. VOGELSTEIN B
AND BODMER WF. (1991). PCR-based detection of two Mspl
polymorphic sites at D18S8. Nucleic Acids Res., 19, 6983.
SCHECK AC AND COONS SW. (1993). Expression of the tumor
suppressor gene DCC in human gliomas. Cancer Res.. 53,
5605-5609.
TANAKA K. OSHIMURA M. KIKUCHI R. SEKI M. HAYASHI T AND
MIYAKI M. (1991). Suppression of tumorigenicity in human
colon carcinoma cells by introduction of normal chromosome 5
or 18. Nature, 349, 340-343.
UCHINO S, TSUDA H. NOGUCHI M. YOKOTA J, TERADA M. SAITO
T. KOBAYASHI M. SUGIMURA T AND HIROHASHI S. (1992).
Frequent loss of heterozygosity at the DCC locus in gastric
cancer. Cancer Res.. 52, 3099-3102.